STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 50, 2015, Pages 15408-15413

  Demaria, Olivier ^a   De Gassart, Aude ^b   Coso, Sanja ^a   Gestermann, Nicolas ^a   Di Domizio, Jeremy ^a   Flatz, Lukas ^a   Gaide, Olivier ^a   Michielin, Olivier ^c   Hwu, Patrick ^d   Petrova, Tatiana V ^a,b,e   Martinon, Fabio ^b   Modlin, Robert L ^f   Speiser, Daniel E ^a,b   Gilliet, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e EPFL   (Switzerland)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antitumor immunity; CD8 T cells; STING; Tumor endothelial cells; Type I IFNs

Indexed keywords

ADAPTOR PROTEIN; CYCLIC AMP DERIVATIVE; CYCLIC GMP AMP; CYCLIC GMP DERIVATIVE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERFERON; PROGRAMMED DEATH 1 RECEPTOR; STING PROTEIN; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; CYCLIC GUANOSINE MONOPHOSPHATE-ADENOSINE MONOPHOSPHATE; CYCLIC NUCLEOTIDE; MEMBRANE PROTEIN; MPYS PROTEIN, MOUSE; TUMOR ANTIGEN;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; COLON CANCER; CONTROLLED STUDY; DENDRITIC CELL; ENDOTHELIUM CELL; EX VIVO STUDY; EXPLANT; GROWTH REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR ENDOTHELIAL CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR MODEL; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; EXPERIMENTAL MELANOMA; IMMUNITY; IMMUNOLOGY; INTRALESIONAL DRUG ADMINISTRATION; METABOLISM; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CTLA-4 ANTIGEN; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENDOTHELIAL CELLS; IMMUNITY; INJECTIONS, INTRALESIONAL; INTERFERON TYPE I; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE, INBRED C57BL; NEOPLASMS; NUCLEOTIDES, CYCLIC; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION;

EID: 84950141423     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1512832112     Document Type: Article

References (30)

1. Luke JJ, Hodi FS (2013) Ipilimumab, vemurafenib, dabrafenib, and trametinib: Syn-ergistic competitors in the clinical management of BRAF mutant malignant melanoma. Oncologist 18(6):717-725.
2. Pittet MJ, et al. (1999) High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 190(5):705-715.
3. Valmori D, et al. (2001) Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res 61(2):509-512.
4. Hodi FS, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711-723.
5. Hamid O, et al. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2):134-144.
6. Wenzel J, et al. (2005) Type I interferon-associated recruitment of cytotoxic lymphocytes: A common mechanism in regressive melanocytic lesions. Am J Clin Pathol 124(1):37-48.
7. Fuertes MB, et al. (2011) Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J Exp Med 208(10):2005-2016.
8. Diamond MS, et al. (2011) Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208(10):1989-2003.
9. Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S (2010) Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest 120(4):1151-1164.
10. Takaoka A, et al. (2007) DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448(7152):501-505.
11. Unterholzner L, et al. (2010) IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol 11(11):997-1004.
12. Zhang Z, et al. (2011) The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat Immunol 12(10):959-965.
13. Tanaka Y, Chen ZJ (2012) STING specifies IRF3 phosphorylation by TBK1 in the cyto-solic DNA signaling pathway. Sci Signal 5(214):ra20.
14. Abe T, et al. (2013) STING recognition of cytoplasmic DNA instigates cellular defense. Mol Cell 50(1):5-15.
15. Gao P, et al. (2013) Cyclic [G(2′, 5′)pA(3′, 5′)p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell 153(5):1094-1107.
16. Ablasser A, et al. (2013) cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING. Nature 498(7454):380-384.
17. Woo SR, et al. (2014) STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41(5):830-842.
18. Deng L, et al. (2014) STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41(5):843-852.
19. Ackermann J, et al. (2005) Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res 65(10): 4005-4011.
20. Pencheva N, Buss CG, Posada J, Merghoub T, Tavazoie SF (2014) Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation. Cell 156(5):986-1001.
21. Ishikawa H, Ma Z, Barber GN (2009) STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461(7265):788-792.
22. Roh MR, et al. (2013) Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice. Melanoma Res 23(2):114-124.
23. Shibata S, et al. (2006) Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene. J Immunol 177(6):3564-3576.
24. Tough DF, Borrow P, Sprent J (1996) Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272(5270):1947-1950.
25. Stein SC, Lam E, Falck-Pedersen E (2012) Cell-specific regulation of nucleic acid sensor cascades: A controlling interest in the antiviral response. J Virol 86(24):13303-13312.
26. Ma F, et al. (2015) Positive feedback regulation of type I interferon by the interferon-stimulated gene STING. EMBO Rep 16(2):202-212.
27. Ehnfors J, et al. (2009) Horizontal transfer of tumor DNA to endothelial cells in vivo. Cell Death Differ 16(5):749-757.
28. Ablasser A, et al. (2013) Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature 503(7477):530-534.
29. Wolchok JD, et al. (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122-133.
30. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039-2049.